首页> 外文OA文献 >Unaltered hepatic oxidative phosphorylation and mitochondrial permeability transition in wistar rats treated with nimesulide: Relevance for nimesulide toxicity characterization
【2h】

Unaltered hepatic oxidative phosphorylation and mitochondrial permeability transition in wistar rats treated with nimesulide: Relevance for nimesulide toxicity characterization

机译:尼美舒利治疗的wistar大鼠肝肝氧化磷酸化水平和线粒体通透性转变未改变:尼美舒利毒性表征的相关性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nonsteroidal anti-inflammatory drugs have been associated with hepatotoxicity in susceptible patients. One such example is nimesulide, a preferential cyclooxygenase 2-inhibitor, widely used for the treatment of inflammation and pain. It was suggested that nimesulide could exert its hepatotoxicity by altering hepatic mitochondrial function, which was demonstrated in vitro. The objective of this study was to verify whether liver mitochondria isolated from rats treated with doses of nimesulide well above therapeutic levels possessed decreased calcium tolerance and oxidative phosphorylation, which indicates in vivo nimesulide mitochondrial toxicity. Male and female rats received nimesulide or its vehicle twice daily, for 5 days, and were killed on the seventh day for the isolation of liver mitochondria. Mitochondrial respiration, transmembrane electric potential, and calcium tolerance were characterized in all experimental groups. Nimesulide had no effect on liver mitochondrial function. Indexes of mitochondrial integrity, calcium loading capacity, and oxidative phosphorylation efficiency were unchanged between liver mitochondria from treated and control animals. In the animals tested, no evidence of degraded mitochondrial function due to nimesulide administration could be found. The results corroborate the notion that despite recognized in vitro mitochondrial toxicity, nimesulide does not cause detectable mitochondrial dysfunction in Wistar rats, even when administered in much higher concentrations than those known to have anti-inflammatory effects. © 2007 Wiley Periodicals, Inc. J Biochem Mol Toxicol 21:53-61, 2007; Published online in Wiley InterScience (). DOI 10.1002/jbt.20159
机译:非甾体抗炎药已与易感患者的肝毒性有关。一个这样的例子是尼美舒利,一种优选的环加氧酶2-抑制剂,其广泛用于治疗炎症和疼痛。提示尼美舒利可通过改变肝线粒体功能发挥其肝毒性作用,这在体外已得到证实。这项研究的目的是验证从远远高于治疗水平的尼美舒利治疗的大鼠中分离出的肝线粒体是否具有降低的钙耐受性和氧化磷酸化,这表明体内尼美舒利线粒体毒性。雄性和雌性大鼠每天两次接受尼美舒利或其媒介物,共5天,并在第七天处死以分离肝线粒体。线粒体呼吸,跨膜电位和钙耐受性在所有实验组中进行了表征。尼美舒利对肝线粒体功能无影响。在治疗和对照动物的肝线粒体之间,线粒体完整性,钙负荷能力和氧化磷酸化效率的指标没有变化。在所测试的动物中,没有发现由于施用尼美舒利导致线粒体功能降低的证据。该结果证实了以下观点:尽管公认的体外线粒体毒性,尼美舒利在Wistar大鼠中也不会引起可检测的线粒体功能障碍,即使以比已知具有抗炎作用的浓度高得多的浓度给药也是如此。 ©2007 Wiley Periodicals,Inc. J Biochem Mol Toxicol 21:53-61,2007;在线发布于Wiley InterScience()。 DOI 10.1002 / jbt.20159

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号